Clinical Trials Browser

Phase 2 × Lymphoma, B-Cell × ibritumomab tiuxetan × Clear all

NCT01434472 2021-07-20

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase 2 Terminated

20 enrolled 15 charts

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00220285 2014-12-30

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00138086 2006-09-08

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, B-Cell